NCT04786444View on ClinicalTrials.gov

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

409

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

July 22, 2021

Study Completion Date

January 26, 2022

Conditions
Chikungunya Virus Infection
Interventions
BIOLOGICAL

Biological Vaccine VLA1553

Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate

Trial Locations (12)

14609

Rochester Clinical Research, Rochester

20910

Walter Reed Amy Institute of Research, Silver Spring

32081

St. Johns Center for Clinical Research, Ponte Vedra

33134

AMR Miami, Coral Gables

33912

AMR Fort Myers, Fort Myers

37919

AMR Knoxville, Knoxville

40509

AMR Lexington, Lexington

64114

Alliance for Multispecialty Research (AMR), Kansas City

67205

AMR Wichita West, Wichita

68134

Meridian Clinical Research, Omaha

77375

Dynamed Clinical Research, Tomball

89104

Wr-Crcn, Llc, Las Vegas

All Listed Sponsors
lead

Valneva Austria GmbH

INDUSTRY

NCT04786444 - Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults | Biotech Hunter | Biotech Hunter